PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer
PharmaMar S.A. (Madrid:PHM) said Zepsyre lurbinectedin (PM01183, PM1183) missed the primary endpoint of improving progression-free survival (PFS) vs. topotecan or pegylated liposomal doxorubicin in the Phase III CORAIL trial to treat platinum-resistant ovarian cancer. The company said PFS was the same in all three treatment arms, but did not disclose details or next steps. Data are slated to be presented at a future cancer conference.
The open-label, U.S. trial’s secondary endpoints include overall survival (OS), patient-reported outcomes and overall response rate (ORR)...
BCIQ Company Profiles
BCIQ Target Profiles